- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Therapeutic Options for Small Cell Lung Cancer
Authors
Keywords
-
Journal
Current Oncology Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-23
DOI
10.1007/s11912-023-01465-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
- (2023) Yi Zhang et al. CLINICAL CANCER RESEARCH
- Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study
- (2023) Luis Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials
- (2023) Beatrice Noce et al. Frontiers in Pharmacology
- CAR-T Therapies in Solid Tumors: Opportunities and Challenges
- (2023) Grace Guzman et al. Current Oncology Reports
- Apatinib as maintenance therapy following standard first‐line chemotherapy in extensive disease small cell lung cancer: A phase II single‐arm trial
- (2022) Fei Teng et al. Thoracic Cancer
- Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
- (2022) Loïc Reppel et al. Journal for ImmunoTherapy of Cancer
- Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2022) Jie Wang et al. LANCET ONCOLOGY
- A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer
- (2022) Chang Liu et al. Thoracic Cancer
- Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
- (2022) Patrick Schöffski et al. Journal for ImmunoTherapy of Cancer
- Update in TIGIT Immune-Checkpoint Role in Cancer
- (2022) Tiziana Annese et al. Frontiers in Oncology
- Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer
- (2022) Sanaz Taromi et al. CANCER LETTERS
- Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
- (2022) Tiandong Kong et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
- (2022) Emiliano Calvo et al. INVESTIGATIONAL NEW DRUGS
- SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
- (2022) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy
- (2022) Nannan Zhang et al. CANCER LETTERS
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
- (2022) Ying Cheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial
- (2022) Penella Woll et al. LUNG CANCER
- Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
- (2022) Santiago Ponce Aix et al. Lancet Respiratory Medicine
- Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer
- (2022) Alessio Stefani et al. Frontiers in Oncology
- Harnessing DLL3 inhibition: From old promises to new therapeutic horizons
- (2022) Diego Luigi Cortinovis et al. Frontiers in Medicine
- ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling
- (2021) Meng Zheng et al. Aging-US
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
- (2021) Carl M. Gay et al. CANCER CELL
- Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis
- (2021) Mingrui Zhu et al. CANCER RESEARCH
- Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study
- (2021) Fiona Blackhall et al. Journal of Thoracic Oncology
- A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer
- (2021) Jyoti Malhotra et al. Journal of Thoracic Oncology
- DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution
- (2021) Lei Zhao et al. ONCOGENE
- First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
- (2021) A. Ortega-Franco et al. ESMO Open
- Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study
- (2021) Ying Cheng et al. BRITISH JOURNAL OF CANCER
- Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
- (2021) Giuseppe Curigliano et al. CLINICAL CANCER RESEARCH
- Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
- (2021) Lauren Averett Byers et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-stage Small-cell Lung Cancer
- (2021) Lauren Averett Byers et al. Clinical Lung Cancer
- OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
- (2021) T. Owonikoko et al. Journal of Thoracic Oncology
- Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study
- (2021) Xinghao Ai et al. Journal of Thoracic Oncology
- Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study
- (2021) Melissa L. Johnson et al. Journal of Thoracic Oncology
- Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer
- (2021) Zibo Zhao et al. CANCER RESEARCH
- A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC
- (2021) Christine L. Hann et al. Journal of Thoracic Oncology
- Molecular Subtypes of Primary Small Cell Lung Cancer Tumors and Their Associations with Neuroendocrine and Therapeutic Markers
- (2021) Song Qu et al. Journal of Thoracic Oncology
- All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC
- (2021) Dipesh Uprety et al. Journal of Thoracic Oncology
- Angiogenesis Inhibitors in Small Cell Lung Cancer
- (2021) Agnese Montanino et al. Frontiers in Oncology
- Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer
- (2021) Aakash Desai et al. LUNG CANCER
- Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium
- (2021) Jasmine Chen et al. ONCOGENE
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
- (2020) José Trigo et al. LANCET ONCOLOGY
- The rare YAP1 subtype of Small Cell Lung Cancer revisited in a biobank of 39 Circulating Tumour Cell Patient Derived eXplant models (CDX): A brief report
- (2020) Sarah M. Pearsall et al. Journal of Thoracic Oncology
- Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
- (2020) David Dora et al. Molecular Oncology
- Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization
- (2020) Marina K. Baine et al. Journal of Thoracic Oncology
- Targeting the epigenetic regulation of antitumour immunity
- (2020) Simon J. Hogg et al. NATURE REVIEWS DRUG DISCOVERY
- SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures
- (2020) Camille Tlemsani et al. Cell Reports
- FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer
- (2020) Sonia Singh et al. CLINICAL CANCER RESEARCH
- Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer
- (2020) Yang Zheng et al. CANCER LETTERS
- YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype
- (2020) Taofeek K. Owonikoko et al. Journal of Thoracic Oncology
- The role of immunotherapy in small cell lung cancer
- (2019) A. Calles et al. Clinical & Translational Oncology
- Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
- (2019) Daniel Carvajal-Hausdorf et al. Journal for ImmunoTherapy of Cancer
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
- (2019) Arnaud Augert et al. Science Signaling
- DLL 3 regulates the migration and invasion of small cell lung cancer by modulating Snail
- (2019) Megumi Furuta et al. CANCER SCIENCE
- Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study
- (2019) Anish Thomas et al. Journal of Thoracic Oncology
- MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
- (2019) Milind D. Chalishazar et al. CLINICAL CANCER RESEARCH
- DLL3: an emerging target in small cell lung cancer
- (2019) Dwight H. Owen et al. Journal of Hematology & Oncology
- Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
- (2019) Todd M. Bauer et al. Journal of Thoracic Oncology
- Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study
- (2019) Yanjun Xu et al. BRITISH JOURNAL OF CANCER
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
- (2019) Marian L. Burr et al. CANCER CELL
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
- (2019) Daniel Morgensztern et al. CLINICAL CANCER RESEARCH
- Challenging the recalcitrant disease—developing molecularly driven treatments for small cell lung cancer
- (2019) Daisy W.S. Mak et al. EUROPEAN JOURNAL OF CANCER
- A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstline induction chemotherapy in extensive stage small cell lung cancer
- (2019) Hao Luo et al. INVESTIGATIONAL NEW DRUGS
- Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
- (2019) Hibiki Udagawa et al. LUNG CANCER
- Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
- (2019) Anna F. Farago et al. Cancer Discovery
- Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
- (2019) Xi Chen et al. Acta Pharmaceutica Sinica B
- The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis
- (2019) Matthew G. Oser et al. GENES & DEVELOPMENT
- Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
- (2019) Taofeek K. Owonikoko et al. Journal of Thoracic Oncology
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung
- (2018) Sanjeeve Balasubramaniam et al. ANTI-CANCER DRUGS
- Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)
- (2018) Jong-Mu Sun et al. BRITISH JOURNAL OF CANCER
- LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
- (2018) Wanqiang Sheng et al. CELL
- A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer
- (2018) Paul Ponath et al. CLINICAL CANCER RESEARCH
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models
- (2018) Denise L. Crossland et al. ONCOGENE
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition
- (2018) Deshui Jia et al. Cancer Discovery
- Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
- (2018) Taofeek K. Owonikoko et al. JOURNAL OF CLINICAL ONCOLOGY
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
- (2017) Wenwen Du et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
- (2017) Marcello Tiseo et al. JOURNAL OF CLINICAL ONCOLOGY
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- (2017) Charles M Rudin et al. LANCET ONCOLOGY
- Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer
- (2017) Karen McColl et al. Oncotarget
- Epigenetic Therapeutics: A New Weapon in the War Against Cancer
- (2016) Nita Ahuja et al. Annual Review of Medicine
- Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
- (2016) Chun-Hao Pan et al. BMC CANCER
- Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)
- (2016) Chandra P. Belani et al. CANCER
- Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
- (2016) Manisha H. Shah et al. INVESTIGATIONAL NEW DRUGS
- Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
- (2016) Paul A. Bunn et al. Journal of Thoracic Oncology
- A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer
- (2016) M. Catherine Pietanza et al. LUNG CANCER
- A phase II study of nintedanib in patients with relapsed small cell lung cancer
- (2016) Ji-Youn Han et al. LUNG CANCER
- Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
- (2016) G. Santamaria Nunez et al. MOLECULAR CANCER THERAPEUTICS
- Histone Modifications and Cancer
- (2016) James E. Audia et al. Cold Spring Harbor Perspectives in Biology
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs
- (2016) Mark D. Borromeo et al. Cell Reports
- Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells
- (2016) Fei Yan et al. PLoS One
- Driver gene classification reveals a substantial overrepresentation of tumor suppressors among very large chromatin-regulating proteins
- (2016) Zeev Waks et al. Scientific Reports
- Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†
- (2015) J.-L. Pujol et al. ANNALS OF ONCOLOGY
- Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition
- (2015) C. Allison Stewart et al. CANCER CELL
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance)
- (2015) Neal E. Ready et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
- (2015) Bohuslav Melichar et al. LANCET ONCOLOGY
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2
- (2015) J T Poirier et al. ONCOGENE
- Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study
- (2014) P. Schoffski et al. ANNALS OF ONCOLOGY
- Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer
- (2014) Corey J. Langer et al. LUNG CANCER
- Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) M. Fruh et al. ANNALS OF ONCOLOGY
- DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer
- (2013) J. Cao et al. CANCER RESEARCH
- Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study
- (2013) David R. Spigel et al. Clinical Lung Cancer
- Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer
- (2013) J. T. Poirier et al. JNCI-Journal of the National Cancer Institute
- A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer
- (2013) Filippo de Marinis et al. Journal of Thoracic Oncology
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group
- (2012) Giannis Mountzios et al. LUNG CANCER
- Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer
- (2012) David R. Spigel et al. LUNG CANCER
- An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
- (2012) K. E. Hook et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
- (2012) Charles M Rudin et al. NATURE GENETICS
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells
- (2012) S Kalari et al. ONCOGENE
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study
- (2011) Neal E. Ready et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- HIF-1α effects on angiogenic potential in human small cell lung carcinoma
- (2011) Jun Wan et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Small-cell lung cancer
- (2011) Jan P van Meerbeeck et al. LANCET
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer
- (2010) David R. Spigel et al. Journal of Thoracic Oncology
- Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
- (2010) Rebecca Suk Heist et al. Journal of Thoracic Oncology
- Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
- (2010) Gregory A. Otterson et al. Journal of Thoracic Oncology
- Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression
- (2010) Wioleta Luszczek et al. MOLECULAR CANCER THERAPEUTICS
- Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501
- (2009) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
- (2009) M. C. Crisanti et al. MOLECULAR CANCER THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now